Latanoprost Stada (Latanoprost)

Latanoprost binds to prostaglandin F (FP) receptors in the eye’s ciliary body, triggering remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Latanoprost Stada is determined by the prescribing eye‑care professional. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

The safety of latanoprost in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and a strong IOP‑lowering effect. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, latanoprost often provides greater pressure reduction with a favorable dosing convenience, though individual response may vary.

Latanoprost Stada should be stored at ambient temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use to maintain product stability.

The solution is applied as a single drop into the conjunctival sac of the prescribed eye(s) once daily, preferably in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and wait at least five minutes before applying other eye medications.

Serious risks, though rare, include severe eye inflammation (uveitis or iritis), allergic reactions such as swelling or rash, paradoxical increase in intra‑ocular pressure, and potential vision loss. Any sudden eye pain, redness, or visual changes should prompt immediate medical evaluation.

Latanoprost Stada is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in individuals with active ocular infections or inflammation until these conditions are resolved.